A1M Pharma is announcing the company's decision to prioritize the indication acute kidney injuries in conjunction with heart surgery in the long-term clinical development plan for the drug candidate ROSgard. This decision is based on the recently communicated positive results from preclinical studies in relevant research models. After completion of a Phase I trial in healthy subjects, the results of which are expected in the first half of 2019, a Phase Ib trial is planned in this patient group to study safety and evaluate the pharmacodynamic efficacy. Work to prepare for clinical development in the indications preeclampsia and PRRT (kidney protection in connection with radiation therapy) will continue, but will be a lower priority than in the past. The development of a new treatment for preeclampsia remains one of the company's long-term objectives.